# OnCo record rejuv-tx-second-cancers (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-tx-second-cancers/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-tx-second-cancers" ;
  schema:name "Second cancers after allogeneic transplant"@en ;
  schema:alternateName "solid cancers after HCT"@en, "second primary malignancy after transplant"@en, "post-transplant malignancy"@en ;
  schema:description "People who have had a donor transplant develop new, unrelated cancers about twice as often as people of the same age, and by fifteen years about three times as often. Radiation in the conditioning matters most for those irradiated young, and chronic GvHD raises squamous cancers of skin and mouth. Both point at lifelong screening."@en ;
  schema:url <https://onco.cc/technologies/rejuv-tx-second-cancers/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Secondary_malignant_neoplasm> ;
  schema:citation <https://doi.org/10.1182/blood-2008-05-158782>, <https://doi.org/10.1182/blood-2010-07-294629>, <https://doi.org/10.1016/j.bbmt.2011.12.519>, <https://doi.org/10.3324/haematol.2016.150250> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "late-effects", "second-cancer" ;
  onco:related <https://onco.cc/technologies/rejuv-tx-late-effects-overview/>, <https://onco.cc/technologies/rejuv-tx-survival-after-transplant/>, <https://onco.cc/technologies/gvhd-chronic-overview/>, <https://onco.cc/technologies/gvhd-organ-by-organ/>, <https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/>, <https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/total-body-irradiation/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/conditioning-regimen/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/> .